The AHA today submitted comments on the Centers for Medicare & Medicaid Services proposed changes to the Medicare Advantage and Part D prescription drug programs for calendar year 2018. “We agree with CMS’s proposal not to move forward with plans to increase the proportion of the risk adjustment scores that are based on encounter data,” wrote AHA Executive Vice President Tom Nickels. “However, we have ongoing concerns both about the use of encounter data for purposes of risk adjustment and the continued calculation of benchmark caps after inclusion of the quality bonus payments. We also provide additional considerations regarding how to address high and rising drug prices in the Part D program.”

Related News Articles

Headline
The departments of Health and Human Services and the Treasury today approved a Section 1332 waiver for Oregon to implement a five-year reinsurance…
Headline
President Trump today issued an executive order directing the departments of Treasury, Labor and Health and Human Services to consider proposing regulations or…
Headline
Baxter Healthcare Corp., in coordination with the Food and Drug Administration, has agreed to temporarily import certain intravenous drug products, such…
Headline
President Trump yesterday named Eric Hargan as Acting Secretary of Health and Human Services. Confirmed as HHS deputy secretary last week, Hargan previously…
Headline
Hospitals generally support the proposed cancellation of the cardiac and Surgical Hip and Femur Fracture Treatment bundling program and Comprehensive Care for…
Headline
Twenty-three organizations, including the AHA, Friday urged the Centers for Medicare & Medicaid Services to suspend implementation of new draft Medicare…